<DOC>
	<DOC>NCT01466985</DOC>
	<brief_summary>This is a study to evaluate the safety, tolerability, pharmacokinetics, and antiretroviral activity of doravirine (MK-1439) as monotherapy in antiretroviral therapy (ART)-naïve, HIV-1-infected participants.</brief_summary>
	<brief_title>A Study of Doravirine (MK-1439) in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439-005)</brief_title>
	<detailed_description />
	<criteria>Diagnosis of HIV1infection ≥3 months prior to screening Participants with female partner(s) of childbearing potential must agree to use a medically acceptable method of contraception during the study and for 90 days after the last dose of study drug Body Mass Index (BMI) ≤35 kg/m^2 Other than HIV infection, participant's baseline health is judged to be stable No clinically significant abnormality on electrocardiogram (ECG) Participant is ARTnaïve (defined as having never received any antiretroviral agent or ≤30 consecutive days of an investigational antiretroviral agent (excluding an NonNucleoside Reverse Transcriptase Inhibitor [NNRTI]) or ≤60 consecutive days of combination ART not including an NNRTI) Participant is willing to receive no other ART for the duration of the treatment phase of this study. History of stroke, chronic seizures, or major neurological disorder History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological (outside of HIV1 infection), renal, respiratory, or genitourinary abnormalities or diseases History of clinically significant neoplastic disease Participant has used any immune therapy agents or immunosuppressive therapy within 1 month prior to treatment in this study Participant has one or more preexisting risk factors for Torsades de Pointes (New York Heart Association Functional Classification II through IV heart failure, familial longQTsyndrome, uncorrected hypokalemia, QTcF &gt;470 msec) Participant requires or is anticipated to require chronic daily prescription medications Current (active) diagnosis of acute hepatitis due to any cause History of chronic Hepatitis C unless there has been documented cure and/or patient with a positive serologic test for HCV has a negative HCV viral load. Positive Hepatitis B surface antigen Participant is unable to refrain from or anticipates the use of any medication, including prescription and nonprescription drugs or herbal remedies (such as St. John's Wort [Hypericum perforatum]) beginning approximately 2 weeks (or 5 halflives) prior to administration of the initial dose of study drug, throughout the study, until the poststudy visit Participant consumes excessive amounts of alcohol, defined as greater than 3 glasses of alcoholic beverages (1 glass is approximately equivalent to: beer [284 mL/10 ounces], wine [125 mL/4 ounces], or distilled spirits [25 mL/1 ounce]) per day Participant consumes excessive amounts, defined as greater than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, or other caffeinated beverages per day Participant is an excessive smoker (i.e., more than 10 cigarettes/day) and is unwilling to restrict smoking to ≤10 cigarettes per day Major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit Participation in another investigational study within 4 weeks prior to the prestudy (screening) visit History of significant multiple and/or severe allergies (including latex allergy), or has had an anaphylactic reaction or significant intolerability to prescription or nonprescription drugs or food Current regular user (including use of any illicit drugs) or has a history of drug (including alcohol) abuse within approximately 1 year</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>